Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

North America Medicinal Mushroom Market

ID: MRFR/FnB/42884-HCR
200 Pages
Garvit Vyas
Last Updated: April 06, 2026

North America Medicinal Mushroom Market Size, Share, Industry Trend & Analysis Research Report: By Type (Shiitake, Reishi, Maitake, Chaga, Cordyceps, Turkey Tail, Other Types), By Form (Fresh, Dried, Other Form) and By Function (Antioxidant, Immune Enhancer, Anti-Cancer, Skin Care, Other Functions)- Forecast to 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

North America Medicinal Mushroom Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Pharmaceutical, BY Product Type (USD Million)
  49.     4.1.1 Shiitake
  50.     4.1.2 Lion's Mane
  51.     4.1.3 Reishi
  52.     4.1.4 Cordyceps
  53.     4.1.5 Chaga
  54.     4.1.6 Others
  55.   4.2 Pharmaceutical, BY Category (USD Million)
  56.     4.2.1 Organic
  57.     4.2.2 Conventional
  58.   4.3 Pharmaceutical, BY Form (USD Million)
  59.     4.3.1 Fresh
  60.     4.3.2 Processed
  61.     4.3.3 Dried
  62.     4.3.4 Powder
  63.     4.3.5 Others
  64.   4.4 Pharmaceutical, BY Application (USD Million)
  65.     4.4.1 Dietary Supplements
  66.     4.4.2 Food & Beverages
  67.     4.4.3 Personal Care
  68.     4.4.4 Pharmaceuticals
  69.   4.5 Pharmaceutical, BY End-user (USD Million)
  70.     4.5.1 Residential
  71.     4.5.2 Commercial
  72.   4.6 Pharmaceutical, BY Distribution Channel (USD Million)
  73.     4.6.1 Supermarkets & Hypermarkets
  74.     4.6.2 Specialty Stores
  75.     4.6.3 E-commerce
  76. 5 SECTION V: COMPETITIVE ANALYSIS
  77.   5.1 Competitive Landscape
  78.     5.1.1 Overview
  79.     5.1.2 Competitive Analysis
  80.     5.1.3 Market share Analysis
  81.     5.1.4 Major Growth Strategy in the Pharmaceutical
  82.     5.1.5 Competitive Benchmarking
  83.     5.1.6 Leading Players in Terms of Number of Developments in the Pharmaceutical
  84.     5.1.7 Key developments and growth strategies
  85.       5.1.7.1 New Product Launch/Service Deployment
  86.       5.1.7.2 Merger & Acquisitions
  87.       5.1.7.3 Joint Ventures
  88.     5.1.8 Major Players Financial Matrix
  89.       5.1.8.1 Sales and Operating Income
  90.       5.1.8.2 Major Players R&D Expenditure. 2023
  91.   5.2 Company Profiles
  92.     5.2.1 Host Defense (US)
  93.       5.2.1.1 Financial Overview
  94.       5.2.1.2 Products Offered
  95.       5.2.1.3 Key Developments
  96.       5.2.1.4 SWOT Analysis
  97.       5.2.1.5 Key Strategies
  98.     5.2.2 Four Sigmatic (FI)
  99.       5.2.2.1 Financial Overview
  100.       5.2.2.2 Products Offered
  101.       5.2.2.3 Key Developments
  102.       5.2.2.4 SWOT Analysis
  103.       5.2.2.5 Key Strategies
  104.     5.2.3 Om Mushroom Superfood (US)
  105.       5.2.3.1 Financial Overview
  106.       5.2.3.2 Products Offered
  107.       5.2.3.3 Key Developments
  108.       5.2.3.4 SWOT Analysis
  109.       5.2.3.5 Key Strategies
  110.     5.2.4 Real Mushrooms (CA)
  111.       5.2.4.1 Financial Overview
  112.       5.2.4.2 Products Offered
  113.       5.2.4.3 Key Developments
  114.       5.2.4.4 SWOT Analysis
  115.       5.2.4.5 Key Strategies
  116.     5.2.5 Mushroom Wisdom (US)
  117.       5.2.5.1 Financial Overview
  118.       5.2.5.2 Products Offered
  119.       5.2.5.3 Key Developments
  120.       5.2.5.4 SWOT Analysis
  121.       5.2.5.5 Key Strategies
  122.     5.2.6 Fungi Perfecti (US)
  123.       5.2.6.1 Financial Overview
  124.       5.2.6.2 Products Offered
  125.       5.2.6.3 Key Developments
  126.       5.2.6.4 SWOT Analysis
  127.       5.2.6.5 Key Strategies
  128.     5.2.7 Mushroom Science (US)
  129.       5.2.7.1 Financial Overview
  130.       5.2.7.2 Products Offered
  131.       5.2.7.3 Key Developments
  132.       5.2.7.4 SWOT Analysis
  133.       5.2.7.5 Key Strategies
  134.     5.2.8 Mycoformulas (US)
  135.       5.2.8.1 Financial Overview
  136.       5.2.8.2 Products Offered
  137.       5.2.8.3 Key Developments
  138.       5.2.8.4 SWOT Analysis
  139.       5.2.8.5 Key Strategies
  140.   5.3 Appendix
  141.     5.3.1 References
  142.     5.3.2 Related Reports
  143. 6 LIST OF FIGURES
  144.   6.1 MARKET SYNOPSIS
  145.   6.2 NORTH AMERICA MARKET ANALYSIS BY PRODUCT TYPE
  146.   6.3 NORTH AMERICA MARKET ANALYSIS BY CATEGORY
  147.   6.4 NORTH AMERICA MARKET ANALYSIS BY FORM
  148.   6.5 NORTH AMERICA MARKET ANALYSIS BY APPLICATION
  149.   6.6 NORTH AMERICA MARKET ANALYSIS BY END-USER
  150.   6.7 NORTH AMERICA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
  151.   6.8 KEY BUYING CRITERIA OF PHARMACEUTICAL
  152.   6.9 RESEARCH PROCESS OF MRFR
  153.   6.10 DRO ANALYSIS OF PHARMACEUTICAL
  154.   6.11 DRIVERS IMPACT ANALYSIS: PHARMACEUTICAL
  155.   6.12 RESTRAINTS IMPACT ANALYSIS: PHARMACEUTICAL
  156.   6.13 SUPPLY / VALUE CHAIN: PHARMACEUTICAL
  157.   6.14 PHARMACEUTICAL, BY PRODUCT TYPE, 2024 (% SHARE)
  158.   6.15 PHARMACEUTICAL, BY PRODUCT TYPE, 2024 TO 2035 (USD Million)
  159.   6.16 PHARMACEUTICAL, BY CATEGORY, 2024 (% SHARE)
  160.   6.17 PHARMACEUTICAL, BY CATEGORY, 2024 TO 2035 (USD Million)
  161.   6.18 PHARMACEUTICAL, BY FORM, 2024 (% SHARE)
  162.   6.19 PHARMACEUTICAL, BY FORM, 2024 TO 2035 (USD Million)
  163.   6.20 PHARMACEUTICAL, BY APPLICATION, 2024 (% SHARE)
  164.   6.21 PHARMACEUTICAL, BY APPLICATION, 2024 TO 2035 (USD Million)
  165.   6.22 PHARMACEUTICAL, BY END-USER, 2024 (% SHARE)
  166.   6.23 PHARMACEUTICAL, BY END-USER, 2024 TO 2035 (USD Million)
  167.   6.24 PHARMACEUTICAL, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
  168.   6.25 PHARMACEUTICAL, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Million)
  169.   6.26 BENCHMARKING OF MAJOR COMPETITORS
  170. 7 LIST OF TABLES
  171.   7.1 LIST OF ASSUMPTIONS
  172.     7.1.1
  173.   7.2 North America MARKET SIZE ESTIMATES; FORECAST
  174.     7.2.1 BY PRODUCT TYPE, 2025-2035 (USD Million)
  175.     7.2.2 BY CATEGORY, 2025-2035 (USD Million)
  176.     7.2.3 BY FORM, 2025-2035 (USD Million)
  177.     7.2.4 BY APPLICATION, 2025-2035 (USD Million)
  178.     7.2.5 BY END-USER, 2025-2035 (USD Million)
  179.     7.2.6 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
  180.   7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  181.     7.3.1
  182.   7.4 ACQUISITION/PARTNERSHIP
  183.     7.4.1

North America Pharmaceutical Market Segmentation

Pharmaceutical By Product Type (USD Million, 2025-2035)

  • Shiitake
  • Lion's Mane
  • Reishi
  • Cordyceps
  • Chaga
  • Others

Pharmaceutical By Category (USD Million, 2025-2035)

  • Organic
  • Conventional

Pharmaceutical By Form (USD Million, 2025-2035)

  • Fresh
  • Processed
  • Dried
  • Powder
  • Others

Pharmaceutical By Application (USD Million, 2025-2035)

  • Dietary Supplements
  • Food & Beverages
  • Personal Care
  • Pharmaceuticals

Pharmaceutical By End-user (USD Million, 2025-2035)

  • Residential
  • Commercial

Pharmaceutical By Distribution Channel (USD Million, 2025-2035)

  • Supermarkets & Hypermarkets
  • Specialty Stores
  • E-commerce

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓